Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Tenaya Therapeutics, Inc. (TNYA)

Tenaya Therapeutics Q2 net loss widens to $43.4 million on $21.8 million impairment

Negative Impact 3 of 5 earnings Written later

Tenaya Therapeutics reported a second-quarter 2026 net loss of $43.4 million, or $0.20 per share, compared with $23.3 million, or $0.14 per share, a year earlier. The company said the increase was mainly due to a $21.8 million non-cash impairment charge tied to the early termination of its Union City manufacturing facility lease. Cash and cash equivalents fell to $78.1 million at June 30, 2026, from $100.5 million at December 31, 2025, and the company said cash should fund operations through Q3 2027, including a $10.0 million upfront payment from Alnylam.

Key points

  • Net loss of $43.4 million, or $0.20 per share, for the quarter ended June 30, 2026, versus $23.3 million, or $0.14 per share, in the same quarter of 2025
  • $21.8 million non-cash impairment charge related to the early termination of the Union City GMMC facility lease
  • Collaboration revenue of $1.1 million in the quarter, compared with none in the prior-year quarter
  • Cash and cash equivalents of $78.1 million at June 30, 2026, which the company expects to fund planned operations through Q3 2027

The filing

CompanyTenaya Therapeutics, Inc. (TNYA)
Form8-K, current report
Filed with the SECAug 5, 2026, 4:10 PM ET
Accession number0001193125-26-335098

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.